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Key words not in the title:  
chronic suppurative lung disease, eosinophilia, foreign body, strongyloides 
 
Abbreviations: 
BAL  bronchoalveolar lavage 
cHRCT chest high-resolution computed tomography 
CSLD  chronic suppurative lung disease 
CFU  colony-forming units 
CF  cystic fibrosis 
FB  flexible bronchoscopy 
IQR  interquartile range 
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ABSTRACT 
 
Background 
Some pediatric centres perform flexible bronchoscopy (FB) routinely when bronchiectasis is 
suspected. However, there are no published data evaluating this practice. 
Objective  
To evaluate the contribution of FB and bronchoalveolar lavage (BAL) to the initial management of 
children newly diagnosed with non-cystic fibrosis (CF) bronchiectasis.  
Method  
We examined FB and BAL data collected prospectively in 56 children aged 0.8-9.8 years during 
initial investigations for bronchiectasis. Investigations contributed to management if any of the 
following were identified: (1) airway obstruction requiring additional intervention, (2) lower airway 
eosinophilia (BAL eosinophils >2.5%), or (3) BAL fluid culture >104 colony-forming units/mL of a 
respiratory bacterial pathogen requiring change from usual empiric antibiotics. 
Results  
Of the 56 children undergoing FB, there were 25 occasions in 23 children where these procedures 
altered empiric treatment. Lower airway eosinophilia was identified in 19 (34%) children, BAL 
microbiology results led to antibiotic changes in 5 (9%) and an unsuspected foreign body was found 
in another (2%). Strongyloides serology was performed in 38 children, including 12 of the 19 with 
airway eosinophilia, and was positive in 5 of these 12 children (42%).   
Conclusion  
Contrary to some expert recommendations that FB should only be performed when bronchiectasis is 
localized, our data suggest that FB with BAL should at least be included in the initial investigations 
of Indigenous children with non-CF bronchiectasis.    
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INTRODUCTION  
Non-cystic fibrosis (CF) bronchiectasis is recognized increasingly as an important chronic 
respiratory disorder affecting children and adults in both developing and affluent countries.1,2 When 
left untreated, bronchiectasis is associated with infection, persistent airway inflammation and 
deteriorating lung function. Recent evidence however, suggests that effective management of 
bronchiectasis in children can improve or, at least, preserve lung function.3,4 
 
Bronchiectasis has several different etiologies. In affluent regions predisposing disorders, such as 
primary immune deficiency, are found commonly.2,4 However, in a developing world setting and 
amongst some Indigenous populations in affluent countries, recurrent respiratory tract infections 
remain the most commonly recognized factor associated with bronchiectasis in children.5,6 
Irrespective of the likely etiology, flexible bronchoscopy (FB) is recommended by some to exclude 
a foreign body or obstructive lesion.2,7 In addition, bronchoalveolar lavage (BAL) performed during 
FB allows collection of airway specimens for microbiologic analyses and examination of 
inflammatory cell types. There is increasing evidence to support the use of airway cellularity in 
guiding clinical management, particularly if airway eosinophilia is present.8-10 However, FB is an 
invasive procedure, adds to the cost and demand for health services and may not be easily accessible 
(particularly for those living in rural regions). Furthermore, some authorities only recommend FB 
when bronchiectasis affects a single lobe and a foreign body needs to be excluded.11 Although 
Australian and New Zealand guidelines recommend FB as a standard investigation for children with 
bronchiectasis,2 there are no data published to support this. Given the contrary2,11 recommendations, 
we examined the contribution of FB and BAL to the initial clinical management of children in our 
settings undergoing investigations for bronchiectasis and chronic suppurative lung disease (CSLD). 
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MATERIALS AND METHODS 
Study participants 
Fifty-six consecutive children (32 males), aged 0.8-9.8 (median 2.2) years, undergoing chest high-
resolution computed tomography (cHRCT) scans and FB at the Royal Darwin Hospital, Northern 
Territory, Australia between November 2007 and December 2009 to evaluate persistent respiratory 
symptoms and suspected bronchiectasis were recruited prospectively. Clinical and socio-
demographic data (Table 1) were obtained from the parent/guardian and medical records using 
standardized data collection forms. Although the children were in a stable clinical state at the time of 
their investigations 26 were receiving prophylactic antibiotics for their respiratory symptoms and 
another 4 had received antibiotics within the previous 2-weeks for chronic suppurative otitis media, 
a common co-morbidity in our setting. Routine investigations for all children included a full blood 
count, serum concentrations of the major immunoglobulin classes, antibody responses to tetanus 
protein and pneumococcal polysaccharide vaccine antigens and a sweat test.2 As purulent nasal 
discharge is very common amongst children in our setting, nasal cilia biopsies were not performed, 
meaning rare cases of primary ciliary dyskinesia could not be excluded. Written informed consent 
was obtained for all procedures. The human research ethics committee of the Northern Territory 
Department of Health and Families and Menzies School of Health Research approved the study 
(#0763).  
 
 cHRCT scans, bronchoscopy and BAL 
cHRCT scans were performed under general anesthesia, followed immediately by FB (3.8 mm 
external diameter) as described previously.12 Radiographic diagnosis of bronchiectasis was made by 
the attending pediatric respiratory physician (AC) or pediatrician (PB) using standard published 
criteria (inside bronchial diameter-to-adjacent artery ratio > 1).5 BAL followed European 
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Respiratory Society guidelines and was obtained from the most abnormal lobe identified by FB or 
cHRCT scans.13 Two aliquots of sterile normal saline (1 ml/kg, max 10ml for the first and 2ml/kg, 
maximum 20mL, for the second aliquot) were instilled into the lobe and suctioned immediately into 
a mucus trap. The first aliquot was used for microbiologic analysis, the second for cytology. 
Specimens were placed on ice and sent immediately to the Laboratory for processing. Total and 
differential cell counts were performed on unfiltered BAL. A hemocytometer determined total cell 
counts. Cytoslides were prepared with a Cytospin 4 (Thermo Scientific), loading approximately 
5x104 cells per slide and stained with Quick Dip (Fronine, Australia). The macrophage, neutrophil, 
lymphocyte and eosinophil percentages were calculated from a total count of 300 cells.  
 
Routine microbiologic investigations for respiratory bacterial pathogens, including culture for 
Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, 
Pseudomonas aeruginosa and Klebsiella pneumoniae, and staining and culture for mycobacterial 
and fungal pathogens, were performed by the Diagnostic Laboratory at the Royal Darwin Hospital. 
In addition, identification and quantification of H. influenzae, S. pneumoniae and M. catarrhalis 
were performed by our research laboratory by published methods and the diagnostic threshold for a 
lower airway infection set at >104 colony-forming units (CFU)/mL of BAL.12  
 
Definition of FB and BAL data altering clinical management 
We defined a priori that data obtained from FB and BAL contributed to clinical management if any 
of the following were met: (1) identification of unsuspected airway obstruction (eg foreign body or 
airway lesion requiring additional intervention), (2) lower airway eosinophilia (BAL eosinophils 
>2.5%) prompting treatment with inhaled corticosteroids, or (3) respiratory bacterial pathogens >104 
CFU/mL requiring a change in therapy. Locally, oral amoxicillin-clavulanate or parenteral 
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ceftriaxone are used by pediatricians empirically to treat children with either chronic suppurative 
lung disease or bronchiectasis.   
Statistical analyses 
As the data lacked a normal distribution, medians and their inter-quartile range (IQR) were used for 
descriptive data, and non-parametric methods, including chi-square tests for dichotomous outcomes, 
Mann-Whitney U tests for continuous variables and Spearman’s r for correlation were employed for 
analyses. The sensitivity, specificity, negative and positive predictive values of a history of current 
wheeze (within the last 12-months) and peripheral blood eosinophilia (>1.5 x 109/L) for airway 
eosinophilia (>2.5%) were also calculated. A two-tailed P-value <0.05 was considered significant. 
Graph Pad Prism Software (California, USA) was used for most statistical calculations.  
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RESULTS 
Clinical diagnosis 
Bronchiectasis (cHRCT-diagnosis) was identified in 52 of the 56 (93%) children (Table 1). The 4 
remaining children had CSLD and as the Australian and New Zealand guidelines advocate that 
children with CSLD are managed similarly to those with bronchiectasis, the entire cohort is 
described below.   
 
Findings from FB and BAL that altered clinical management 
We identified 25 occasions where FB and BAL altered clinical management in 23 (41%) children 
with two children meeting two criteria (airway eosinophilia and either P. aeruginosa or K. 
pneumoniae). An unsuspected foreign body (chicken bone) in the left main stem bronchus was 
removed from a 5-year old Indigenous girl, but who then did not proceed to BAL. This particular 
child had at least a 3-year history of cough, had been hospitalized for pneumonia on 3 previous 
occasions and the cHRCT scan showed evidence of bronchiectasis in the left lower and right upper 
and lower lobes.   
 
The mean BAL return was 47%. Lower airway infection (>104 CFU/mL) was diagnosed in 25/55 
(45%) children. Lower airway infection rates were not significantly different between children 
taking (13/26; 50%) or not taking (12/29; 41%; P=0.52) antibiotics at the time of FB. Major 
pathogens included H. influenzae (n=16), S. pneumoniae (n=10) and M. catarrhalis (n=9) in 20 
children. However, 5 (9%) required changes to their initial empiric antibiotic treatments as either P. 
aeruginosa (n=4) or K. pneumoniae (n=1) were identified in BAL fluid cultures. The 4 children 
identified with P. aeruginosa infection were aged 0.8-2.5 years and had bronchiectatic changes 
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involving 2-4 lobes. Neither mycobacterial nor fungal pathogens were isolated from any child in the 
study.  
 
Airway differential count 
BAL fluid eosinophilia (>2.5%) was the most common indication for changing clinical 
management. Nineteen children (34%) were identified with airway eosinophilia (Figure 1). The 
median (IQR) eosinophil percentage in BAL fluid was 1.3% (0.3-5.0). Median (IQR) values for 
neutrophils were 14.3% (6.7-47), lymphocytes 6.0% (2-12) and macrophages 66% (38-83), while 
the median (IQR) total cell count was 46 (25-80) x104 per ml of BAL fluid. The percentage of 
airway eosinophils was significantly correlated with the number of peripheral blood eosinophils,     
r= 0.49, P=0.0002 (Figure 2). Absolute airway eosinophil counts also correlated with number of 
peripheral blood eosinophils (r = 0.6886, P=<0.0001). However, a current history of wheeze and 
peripheral blood eosinophilia (>1.5 x109/L) were both unreliable predictors of airway eosinophilia 
(Table 2). Similarly, airway cellularity was not significantly different between children who were, or 
were not, receiving antibiotics at the time of FB [median (IQR) total cell counts, 44 (27-75) vs 47 
(25-84) x 104 per mL of BAL fluid, P=0.87; neutrophil 10.6 (3.8-28.2)% vs 16.6 (8.2-51.2)% 
P=0.15; and eosinophil 1.3 (0.2-3.1)% vs 1.3 (0.3-5.9)% P=0.55 respectively].      
 
After finding lower airway eosinophilia in 7 of the first 18 participants, the next 38 children (12 with 
airway eosinophilia) had strongyloides serology performed at the regional reference laboratory 
(PathWest Laboratory Medicine WA, Australia, IgG by EIA > 0.45 absorbance units). Five 
Indigenous children had positive strongyloides serology, which was accompanied by airway 
eosinophilia (Figure 2) and each child received anti-helminthic therapy. Strongyloides serology was 
either negative (n=6) or equivocal (n=1) in the remaining 7 children with airway eosinophilia. 
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Similarly, children without airway eosinophilia at BAL had negative strongyloides serology, except 
for one child with an airway eosinophil differential percentage of 2.3% who had equivocal 
serological results. Of the 5 children already receiving inhaled corticosteroids, 2 had airway 
eosinophilia, including one child who was seropositive for strongyloides.
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DISCUSSION 
This is the first study to prospectively evaluate the contribution of FB with BAL to the initial 
management of children with non-CF bronchiectasis or CSLD. In 41% of the 56 children studied, 
we found that FB with BAL led to a change in management by identifying lower airway 
eosinophilia and antibiotic-resistant respiratory pathogens and helped discover an unexpected 
inhaled foreign body.  If we had included any respiratory infection instead of infection requiring a 
change from empiric antibiotics, and removal of mucous plugs during bronchoscopy as therapeutic 
interventions the yield of FB could have been even higher. 
 
Airway eosinophilia is associated with several respiratory disorders14 and in adults with 
bronchiectasis, there is evidence of eosinophil activation.15 However, to our knowledge airway 
eosinophilia has not been reported previously in children with bronchiectasis. Published data on 
airway cellularity in children with bronchiectasis are limited, and to date, only neutrophilia has been 
described.16  The importance of finding eosinophilia is that sustained (>6-months) systemic17 and 
lower airway18 eosinophilia can be associated with end-organ damage. Also airway eosinophilia is 
used to help guide corticosteroid therapy in eosinophil-associated airway diseases.10,19 Even using a 
conservative cut-off of 2.5% 20,21 as an indication to commence inhaled corticosteroids while 
waiting to investigate the underlying cause, we found that 34% (19 children) had clinically 
important airway eosinophilia. Importantly, both current wheeze and circulating eosinophilia were 
poor predictors of airway eosinophilia in these children. A sputum eosinophil count of 2-3% is 
considered the threshold for predicting a positive therapeutic outcome from inhaled 
corticosteroids.9,10 However, the threshold used for BAL specimens should be lower as direct 
comparisons between paired BAL and sputum samples indicate that BAL specimens have lower 
eosinophil counts than found in sputum, which may reflect dilution and sampling from peripheral 
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rather than central airways.14 The upper threshold of BAL eosinophil values in pediatric controls 
(age range 0.16-14.5 years) is between 0% and 1.19% (75th percentile).22,23 Published studies have 
used thresholds as low as 1.1% to define airway eosinophilia or as high as 2% to define eosinophilic 
pnuemonia.22,24 However, in the absence of robust clinical data from randomized controlled trials 
using BAL, we chose a conservative threshold for therapeutic intervention. Our data suggest that 
airway cellularity to detect eosinophilia should be considered when investigating children for 
bronchiectasis. However, we do not advocate bronchoscopy is undertaken merely to detect airway 
eosinophilia particularly in selected situations where other simple, non-invasive means of detecting 
airway eosinophilia (such as exhaled nitric oxide measurement in children aged > 4 years) are 
available. 
 
In endemic regions parasitic infections are a common cause of circulating eosinophilia and may also 
result in respiratory symptoms.25 Strongyloides stercoralis is an intestinal nematode endemic to 
Northern and Central Australia26 and as part of its life cycle migrates to the lungs and airways. 
Helminths with a similar respiratory phase including Ancylostoma (hook worm) and Ascaris are 
now uncommon in Australian Indigenous communities.27 While infection can be associated with 
asymptomatic chronic disease, strongyloidiasis can also lead to significant morbidity and even 
mortality in Indigenous Australians.28 Although we were unable to test all children, our data suggest 
that infection with S. stercoralis may contribute to the airway inflammatory profile of some 
Indigenous children with bronchiectasis. Any contribution to airway inflammation potentially 
contributes to airway injury and bronchiectasis and should be investigated and treated when present. 
As this was a cross-sectional study, it is unknown whether the peripheral blood and lower airway 
eosinophilia observed was chronic or transient and if it responded to anti-helminthic or 
corticosteroid therapy. Our data also suggest that strongyloidiasis does not fully explain the high 
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prevalence of lower airway eosinophilia seen in this cohort.27 Allergic bronchopulmonary 
aspergilliosis (ABPA) is another recognized cause of airway eosinophilia. We did not test for 
Aspergillus-specific IgE, but Aspergillus was not detected in the BAL of any of these children. 
Furthermore, Aspergillus is very rare in children with non-CF bronchiectasis (none in 113 
children),29 although it is well described in adults with bronchiectasis.18 
The value of BAL for diagnosing respiratory infection in the pediatric setting is widely recognized. 
Non-typeable H. influenzae, S. pneumoniae and M. catarrhalis are the most commonly detected 
pathogens in children with bronchiectasis12 and this forms the basis for the choice of the initial 
empiric antibiotic therapy for respiratory exacerbations. However, when children with CSLD and 
bronchiectasis are deteriorating despite therapy, BAL cultures can help identify pathogens, such as 
P. aeruginosa, which require different antibiotics for adequate treatment. Similarly, exclusion of 
anatomical airway lesions and obstruction is also important as bronchiectasis and long-term 
pulmonary complications may occur in 25-60% of patients when the diagnosis of foreign body 
airway aspiration is delayed >30-days.7 If obtainable, sputum cultures are an alternative to those 
obtained by BAL from older children, particularly as a means of monitoring treatment. However, 
studies using sputum induction in children are restricted largely to subjects who are at least 6-years 
of age when it can be performed safely and successfully.30 The median age of children in this study 
was 2.2-years, with only 4 children over the age of 6 years and it was therefore not feasible to 
include sputum culture in this study. As spontaneous sputum expectoration in young children is 
unusual, clinicians often have to rely upon FB when seeking suitable lower airway specimens. 
 
The present study has several important limitations. In addition to its cross-sectional nature, only a 
limited number of investigations were performed to detect underlying causes of airway eosinophilia. 
We could not define ‘therapeutic response’ to the multitude of interventions given once the 
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diagnosis was made. Although it is current ‘best practice’ to treat clinically important airway 
eosinophilia, there are no randomized controlled trial data in children on when and how airway 
eosinophilia should be managed. Also, as this study was conducted predominantly in Indigenous 
children from remote communities in Northern Australia, the findings, especially of airway 
eosinophilia, may not be directly applicable to other children with bronchiectasis, either in Australia 
or elsewhere. Another potential limitation is that although 81% of children of children in this study 
had multi-lobed bronchiectasis (33% with 3 or more lobes affected), we sampled from a single lobe, 
as is current practice in our setting. Studies in children with CF have shown that while airway 
inflammation can involve both lungs, the distribution of bacteria between both lungs and within 
lobes from the same lung is often uneven.31,32  It is possible therefore that a similar situation may 
exist in children with non-CF bronchiectasis and future consideration should perhaps be given to 
multi-lobe sampling, particularly in children with extensive bronchiectasis. Regardless, this study 
highlights the value of bronchoscopy in providing detailed, individualized data which can direct 
therapy, a finding which is applicable globally. 
There is accumulating evidence that with early diagnosis and intensive therapy, bronchiectasis can 
be stabilized and lung function preserved.3,4 While the contribution of FB and BAL to the 
management of children with bronchiectasis or CSLD may seem self-evident, this study is the first 
to provide evidence to support this recommendation.2 It also, raises important questions over the 
etiology and consequences of lower airway eosinophilia in children with bronchiectasis, which will 
require additional research.  
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FIGURE LEGENDS 
Figure 1.  
Distribution of eosinophils (a) and neutrophils (b) as a percentage of total airway leukocytes in 
bronchoalveolar lavage fluid from 55 children with bronchiectasis or chronic suppurative lung 
disease. The lower limit for clinically important airway eosinophilia (2.5%) is represented by the 
dashed line. The y axis is a split scale. Cytoslides of BAL show eosinophilia with neutrophilia (c) 
original x400 and neutrophilia (d) original x200. 
 
Figure 2. 
Scatter plot of eosinophil percentages in bronchoalveolar lavage fluid and absolute eosinophil 
counts in peripheral blood (n=54), r=0.49, P=0.0002. Open circles identify children with positive 
strongyloides serology (enzyme immunoassay >0.45 absorbance units). Thresholds for circulating 
and airway eosinophilia are shown by the dashed lines17,20,21 
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Key words not in the title:  
chronic suppurative lung disease, eosinophilia, foreign body, strongyloides 
 
Abbreviations: 
BAL  bronchoalveolar lavage 
cHRCT chest high-resolution computed tomography 
CSLD  chronic suppurative lung disease 
CFU  colony-forming units 
CF  cystic fibrosis 
FB  flexible bronchoscopy 
IQR  interquartile range 
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ABSTRACT 
 
Background 
Some pediatric centres perform flexible bronchoscopy (FB) routinely when bronchiectasis is 
suspected. However, there are no published data evaluating this practice. 
Objective  
To evaluate the contribution of FB and bronchoalveolar lavage (BAL) to the initial management of 
children newly diagnosed with non-cystic fibrosis (CF) bronchiectasis.  
Method  
We examined FB and BAL data collected prospectively in 56 children aged 0.8-9.8 years during 
initial investigations for bronchiectasis. Investigations contributed to management if any of the 
following were identified: (1) airway obstruction requiring additional intervention, (2) lower airway 
eosinophilia (BAL eosinophils >2.5%), or (3) BAL fluid culture >10
4 
colony-forming units/mL of a 
respiratory bacterial pathogen requiring change from usual empiric antibiotics. 
Results  
Of the 56 children undergoing FB, there were 25 occasions in 23 children where these procedures 
altered empiric treatment. Lower airway eosinophilia was identified in 19 (34%) children, BAL 
microbiology results led to antibiotic changes in 5 (9%) and an unsuspected foreign body was found 
in another (2%). Strongyloides serology was performed in 38 children, including 12 of the 19 with 
airway eosinophilia, and was positive in 5 of these 12 children (42%).   
Conclusion  
Contrary to some expert recommendations by some experts that FB should only be performed when 
bronchiectasis is localized, our data suggest that FB with BAL should at least be included in the 
initial investigations of Indigenous children with non-CF bronchiectasis.    
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INTRODUCTION  
Non-cystic fibrosis (CF) bronchiectasis is recognized increasingly as an important chronic 
respiratory disorder affecting children and adults in both developing and affluent countries.
1,2
 When 
left untreated, bronchiectasis is associated with infection, persistent airway inflammation and 
deteriorating lung function. Recent evidence however, suggests that effective management of 
bronchiectasis in children can improve or, at least, preserve lung function.
3,4
 
 
Bronchiectasis has several different etiologies. In affluent regions predisposing disorders, such as 
primary immune deficiency, are found commonly.
2,4
 However, in a developing world setting and 
amongst some Indigenous populations in affluent countries, recurrent respiratory tract infections 
remain the most commonly recognized factor associated with bronchiectasis in children.
5,6
 
Irrespective of the likely etiology, flexible bronchoscopy (FB) is recommended by some to exclude 
a foreign body or obstructive lesion.
2,7
 In addition, bronchoalveolar lavage (BAL) performed during 
FB allows collection of airway specimens for microbiologic analyses and examination of 
inflammatory cell types. There is increasing evidence to support the use of airway cellularity in 
guiding clinical management, particularly if airway eosinophilia is present.
8-10
 However, FB is an 
invasive procedure, adds to the cost and demand for health services and may not be easily accessible 
(particularly for those living in rural regions). Furthermore, some authorities only recommend FB 
when bronchiectasis affects a single lobe and a foreign body needs to be excluded.
11
 Although 
Australian and New Zealand guidelines recommend FB as a standard investigation for children with 
bronchiectasis,
2
 there are no data published to support this. Given the contrary
2,11
 recommendations, 
we examined the contribution of FB and BAL to the initial clinical management of children in our 
settings undergoing investigations for bronchiectasis and chronic suppurative lung disease (CSLD). 
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MATERIALS AND METHODS 
Study participants 
Fifty-six consecutive children (32 males), aged 0.8-9.8 (median 2.2) years, undergoing chest high-
resolution computed tomography (cHRCT) scans and FB at the Royal Darwin Hospital, Northern 
Territory, Australia between November 2007 and December 2009 to evaluate persistent respiratory 
symptoms and suspected bronchiectasis were recruited prospectively. Clinical and socio-
demographic data (Table 1) were obtained from the parent/guardian and medical records using 
standardized data collection forms. They Although the children were in a stable clinical state at the 
time of their investigations 26 were receiving prophylactic antibiotics for their respiratory symptoms 
and another 4 had received antibiotics within the previous 2-weeks for chronic suppurative otitis 
media, a common co-morbidity in our setting. Clinical and sociodemographic data (Table 1) were 
obtained from the parent/guardian and medical records using standardized data collection forms. 
Routine investigations for all children included a full blood count, serum concentrations of the major 
immunoglobulin classes, antibody responses to tetanus protein and pneumococcal polysaccharide 
vaccine antigens and a sweat test.
 2
 As purulent nasal discharge is very common amongst children in 
our setting, nasal cilia biopsies were not performed, meaning rare cases of primary ciliary dyskinesia 
could not be excluded. Written informed consent was obtained for all procedures. The human 
research ethics committee of the Northern Territory Department of Health and Families and Menzies 
School of Health Research approved the study (#07600763).  
 
 cHRCT scans, bronchoscopy and BAL 
cHRCT scans were performed under general anesthesia, followed immediately by FB (3.8 mm 
external diameter) as described previously.
12
 Radiographic diagnosis of bronchiectasis was made by 
the attending pediatric respiratory physician (AC) or pediatrician (PB) using standard published 
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criteria (inside bronchial diameter-to-adjacent artery ratio > 1).
5
 BAL followed European 
Respiratory Society guidelines and was obtained from the most abnormal lobe identified by FB or 
cHRCT scans.
13
 Two aliquots of sterile normal saline (1 ml/kg, max 10ml for the first and 2ml/kg, 
maximum 20mL, for the second aliquot) were instilled into the lobe and suctioned immediately into 
a mucus trap. The mean BAL return was 47%. The first aliquot was used for microbiologic analysis, 
the second for cytology. Specimens were placed on ice and sent immediately to the Laboratory for 
processing. Total and differential cell counts were performed on unfiltered BAL. A hemocytometer 
determined total cell counts. Cytoslides were prepared with a Cytospin 4 (Thermo Scientific), 
loading approximately 5x10
4
 cells per slide and stained with Quick Dip (Fronine, Australia). The 
macrophage, neutrophil, lymphocyte and eosinophil percentages were calculated from a total count 
of 300 cells.  
 
Routine microbiologic investigations for respiratory bacterial pathogens, including culture for 
Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, 
Pseudomonas aeruginosa and Klebsiella pneumoniae, and staining and culture for mycobacterial 
and fungal pathogens, were performed by the Diagnostic Laboratory at the Royal Darwin Hospital. 
In addition, identification and quantification of H. influenzae, S. pneumoniae and M. catarrhalis 
were performed by our research laboratory by published methods and the diagnostic threshold for a 
lower airway infection set at >10
4
 colony-forming units (CFU)/mL of BAL.
12
  
 
Definition of FB and BAL data altering clinical management 
We defined a priori that data obtained from FB and BAL contributed to clinical management if any 
of the following were met: (1) identification of unsuspected airway obstruction (eg foreign body or 
airway lesion requiring additional intervention), (2) lower airway eosinophilia (BAL eosinophils 
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>2.5%) prompting treatment with inhaled corticosteroids, or (3) respiratory bacterial pathogens >10
4
 
CFU/mL requiring a change in therapy. Locally, oral amoxicillin-clavulanate or parenteral 
ceftriaxone are used by pediatricians empirically to treat children with either chronic suppurative 
lung disease or bronchiectasis.
2
   
Statistical analyses 
As the data lacked a normal distribution, medians and their inter-quartile range (IQR) were used for 
descriptive data, and non-parametric methods, including chi-square tests for dichotomous outcomes, 
Mann-Whitney U tests for continuous variables and Spearman’s r for correlation were employed for 
analyses. The sensitivity, specificity, negative and positive predictive values of a history of current 
wheeze (within the last 12-months) and peripheral blood eosinophilia (>1.5 x 10
9
/L) for airway 
eosinophilia (>2.5%) were also calculated. A two-tailed P-value <0.05 was considered significant. 
Graph Pad Prism Software (California, USA) was used for most statistical calculations.  
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RESULTS 
Clinical diagnosis 
Bronchiectasis (cHRCT-diagnosis) was identified in 52 of the 56 (93%) children (Table 1). The 4 
remaining children had CSLD .and as the Australian and New Zealand guidelines advocate that 
children with CSLD are managed similarly to those with bronchiectasis, the entire cohort is 
described below.     
 
Findings from FB and BAL that altered clinical management 
We identified 25 occasions where FB and BAL altered clinical management in 23 (41%) children 
with two children meeting two criteria (airway eosinophilia and either P. aeruginosa or K. 
pneumoniae). An unsuspected foreign body (chicken bone) in the left main stem bronchus was 
removed from a 5-year old Indigenous girl, but who then did not proceed to BAL. This particular 
child had at least a 3-year history of cough, had been hospitalized for pneumonia on 3 previous 
occasions and the cHRCT scan showed evidence of bronchiectasis in the left lower and right upper 
and lower lobes.   
 
The mean BAL return was 47%. Lower airway infection (>10
4
 CFU/mL) was diagnosed in 25/55 
(45%) children. Lower airway infection rates were not significantly different between children 
taking (13/26; 50%) or not taking (12/29; 41%; P=0.52) antibiotics at the time of FB. Major  
pathogens included H. influenzae (n=16), S. pneumoniae (n=10) and M. catarrhalis (n=9) in 20 
children. However, 5 (9%) required changes to their initial empiric antibiotic treatments as either P. 
aeruginosa (n=4) or K. pneumoniae (n=1) were identified in BAL fluid cultures. The 4 children 
identified with P. aeruginosa infection were aged 0.8-2.5 years and had bronchiectatic changes 
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involving 2-4 lobes. Neither mycobacterial nor fungal pathogens were isolated from any child in the 
study.  
 
Airway differential count 
BAL fluid eosinophilia (>2.5%) was the most common indication for changing clinical 
management. Nineteen children (34%) were identified with airway eosinophilia (Figure 1). The 
median (IQR) eosinophil percentage in BAL fluid was 1.3% (0.3-5.0). Median (IQR) values for 
neutrophils were 14.3% (6.7-47), lymphocytes 6.0% (2-12) and macrophages 66% (38-83), while 
the median (IQR) total cell count was 46 (25-80) x10
4
 per ml of BAL fluid. The percentage of 
airway eosinophils was significantly correlated with the number of peripheral blood eosinophils,     
r= 0.49, P=0.0002 (Figure 2). Absolute airway eosinophil counts also correlated with number of 
peripheral blood eosinophils (r = 0.6886, P=<0.0001). However, a current history of wheeze and 
peripheral blood eosinophilia (>1.5 x10
9
/L) were both unreliable predictors of airway eosinophilia 
(Table 2). Similarly, airway cellularity was not significantly different between children who were, or 
were not, receiving antibiotics at the time of FB [median (IQR) total cell counts, 0.44 (0.27-0.75) vs 
0.47 (0.25-0.84) x 10
4
 per mL of BAL fluid, P=0.87; neutrophil 10.6 (3.8-28.2)% vs 16.6 (8.2-
51.2)% P=0.15; and eosinophil 1.3 (0.2-3.1)% vs 1.3 (0.3-5.9)% P=0.55 respectively].      
 
After finding lower airway eosinophilia in 7 of the first 18 participants, the next 38 children (12 with 
airway eosinophilia) had strongyloides serology performed at the regional reference laboratory 
(PathWest Laboratory Medicine WA, Australia, IgG by EIA > 0.45 absorbance units). Five 
Indigenous children had positive strongyloides serology, which was accompanied by airway 
eosinophilia (Figure 2) and each child received anti-helminthic therapy. Strongyloides serology was 
either negative (n=6) or equivocal (n=1) in the remaining 7 children with airway eosinophilia. 
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Similarly, children without airway eosinophilia at BAL had negative strongyloides serology, except 
for one child with an airway eosinophil differential percentage of 2.3% who had equivocal 
serological results. Of the 5 children already receiving inhaled corticosteroids, 2 had airway 
eosinophilia, including one child who was seropositive for strongyloides.
Page 32 of 47
John Wiley & Sons, Inc.
Pediatric Pulmonology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 12
DISCUSSION 
This is the first study to prospectively evaluate the contribution of FB with BAL to the initial 
management of children with non-CF bronchiectasis or CSLD. In 41% of the 56 children studied, 
we found that FB with BAL lead to a change in management by identifying lower airway 
eosinophilia and antibiotic-resistant respiratory pathogens and helped discover an unexpected 
inhaled foreign body.  If we had included any respiratory infection instead of infection requiring a 
change from empiric antibiotics, and removal of mucous plugs during bronchoscopy as a therapeutic 
interventions the yield of FB could have been even higher. 
 
Airway eosinophilia is associated with several respiratory disorders
14
 and in adults with 
bronchiectasis, there is evidence of eosinophil activation.
15
 However, to our knowledge airway 
eosinophilia has not been reported previously in children with bronchiectasis. Published data on 
airway cellularity in children with bronchiectasis are limited, and to date, only neutrophilia has been 
described.
16
  The importance of finding eosinophilia is that sustained (>6-months) systemic
17
 and 
lower airway
18
 eosinophilia can be associated with end-organ damage. Also airway eosinophilia is 
used to help guide corticosteroid therapy in eosinophil-associated airway diseases.
10,19
 Even using a 
conservative cut-off of 2.5% 
20,21
 as an indication to commence inhaled corticosteroids while 
waiting to investigate the underlying cause, we found that 34% (19 children) had clinically 
important airway eosinophilia. Importantly, both current wheeze and circulating eosinophilia were 
poor predictors of airway eosinophilia in these children. A sputum eosinophil count of 2-3% is 
considered the threshold for predicting a positive therapeutic outcome from inhaled 
corticosteroids.
9,10
 However, the threshold used for BAL specimens should be lower as direct 
comparisons between paired BAL and sputum samples indicate that BAL specimens have lower 
eosinophil counts than found in sputum, which may reflect dilution and sampling from peripheral 
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rather than central airways.
14
 The upper threshold of BAL eosinophil values in pediatric controls 
(age range 0.16-14.5 years) is between 0% and 1.19% (75
th
 percentile).
22,23
 Published studies have 
used thresholds as low as 1.1% to define airway eosinophilia or as high as 2% to define eosinophilic 
pnuemonia.
22,24
 However, in the absence of robust clinical data from randomized controlled trials 
using BAL, we chose a conservative threshold for therapeutic intervention. Our data suggest that 
airway cellularity to detect eosinophilia should be considered when investigating children for 
bronchiectasis. However, we do not advocate bronchoscopy is undertaken merely to detect airway 
eosinophilia particularly in selected situations where other simple, non-invasive means of detecting 
airway eosinophilia (such as exhaled nitric oxide measurement in children aged > 4 years) are 
available.  
 
Several disorders are associated with peripheral blood and airway eosinophilia. In endemic regions 
parasitic infections are a common cause of circulating eosinophilia and may also result in respiratory 
symptoms.
25
 Strongyloides stercoralis is an intestinal nematode endemic to Northern and Central 
Australia
26
 and as part of its life cycle migrates to the lungs and airways. Helminths with a similar 
respiratory phase including Ancylostoma (hook worm) and Ascaris are now uncommon in 
Australian Indigenous communities.
27
 While infection can be associated with asymptomatic chronic 
disease, strongyloidiasis can also lead to significant morbidity and even mortality in Indigenous 
Australians.
28
 Although we were unable to test all children, our data suggest that infection with S. 
stercoralis may contributes to the airway inflammatory profile of some Indigenous children with 
bronchiectasis. Any contribution to airway inflammation potentially contributes to airway injury and 
bronchiectasis and should be investigated and treated when present.  in our cohort. As this was a 
cross-sectional study, it is unknown whether the peripheral blood and lower airway eosinophilia 
observed was chronic or transient and if it responded to anti-helminthic or corticosteroid therapy. 
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Nevertheless, oOur data also suggest that strongyloidiasis does not fully explain the high prevalence 
of lower airway eosinophilia seen in this cohort. Moreover, other helminths that migrate through the 
lung as part of their life cycle are now uncommon in Australia.
27
  Allergic bronchopulmonary 
aspergilliosis (ABPA) is another recognized cause of airway eosinophilia. We did not test for 
Aspergillus-specific IgE, but Aspergillus was not detected in the BAL of any of these children. 
Furthermore, Aspergillus is very rare in children with non-CF bronchiectasis (none in 113 
children),
29
 although it is well described in adults with bronchiectasis. Thus, the etiology of our 
novel finding of clinically important airway eosinophilia remains unknown, but requires further 
study as it may contribute to airway injury
18
 and severity of bronchiectasis.  
 
The value of BAL for diagnosing respiratory infection in the pediatric setting is widely recognized. 
Non-typeable H. influenzae, S. pneumoniae and M. catarrhalis are the most commonly detected 
pathogens in children with bronchiectasis
12
 and this forms the basis for the choice of the initial 
empiric antibiotic therapy for respiratory exacerbations. However, when children with CSLD and 
bronchiectasis are deteriorating despite therapy, BAL cultures can help identify pathogens, such as 
P. aeruginosa, which require different antibiotics for adequate treatment. Similarly, exclusion of 
anatomical airway lesions and obstruction is also important as bronchiectasis and long-term 
pulmonary complications may occur in 25-60% of patients when the diagnosis of foreign body 
airway aspiration is delayed >30-days.
7
 If obtainable, sputum cultures are an alternative to those 
obtained by BAL from older children, particularly as a means of monitoring treatment. However, 
studies using sputum induction in children are restricted largely to subjects who are at least 6-years 
of age when it can be performed safely and successfully.
30
 The median age of children in this study 
was 2.2-years, with only 4 children over the age of 6 years and it was therefore not feasible to 
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include sputum culture in this study. As spontaneous sputum expectoration in young children is 
unusual, clinicians often have to rely upon FB when seeking suitable lower airway specimens. 
 
The present study has several important limitations. In addition to its cross-sectional nature, only a 
limited number of investigations were performed to detect underlying causes of airway eosinophilia. 
We could not define ‘therapeutic response’ to the multitude of interventions given once the 
diagnosis was made. Although it is current ‘best practice’ to treat clinically important airway 
eosinophilia, there are no randomized controlled trial data in children on when and how airway 
eosinophilia should be managed. Also, as this study was conducted predominantly in Indigenous 
children from remote communities in Northern Australia, the findings, especially of airway 
eosinophilia, may not be directly applicable to other children with bronchiectasis, either in Australia 
or elsewhere. Another potential limitation is that although 81% of children of children in this study 
had multi-lobed bronchiectasis (33% with 3 or more lobes affected), we sampled from a single lobe, 
as is current practice in our setting. Studies in children with CF have shown that while airway 
inflammation can involve both lungs, the distribution of bacteria between both lungs and within 
lobes from the same lung is often uneven.
31,32
  It is possible therefore that a similar situation may 
exist in children with non-CF bronchiectasis and future consideration should perhaps be given to 
multi-lobe sampling, particularly in children with extensive bronchiectasis.This study does, 
however, Regardless, this study  highlights the value of bronchoscopy in providing detailed, 
individualized data which can direct therapy, a finding which is applicable globally. 
 
There is accumulating evidence that with early diagnosis and intensive therapy, bronchiectasis can 
be stabilized and lung function preserved.
3,4
 While the contribution of FB and BAL to the 
management of children with bronchiectasis or CSLD may seem self-evident, this study is the first 
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to provide evidence to support this recommendation.
2
 It also, raises important questions over the 
etiology and consequences of lower airway eosinophilia in children with bronchiectasis, which will 
require additional research.  
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FIGURE LEGENDS 
Figure 1.  
Distribution of eosinophils (a) and neutrophils (b) as a percentage of total airway leukocytes in 
bronchoalveolar lavage fluid from 55 children with bronchiectasis or chronic suppurative lung 
disease. The lower limit for clinically important airway eosinophilia (2.5%) is represented by the 
dashed line. The y axis is a split scale. Cytoslides of BAL show eosinophilia with neutrophilia (c) 
original x400 and neutrophilia (d) original x200. 
 
Figure 2. 
Scatter plot of eosinophil percentages in bronchoalveolar lavage fluid and absolute eosinophil 
counts in peripheral blood (n=54), r=0.49, P=0.0002. Open circles identify children with positive 
strongyloides serology (enzyme immunoassay >0.45 absorbance units). Thresholds for circulating 
and airway eosinophilia are shown by the dashed lines
17,20,21
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Table 1:  Sociodemographic, clinical and radiographic characteristics of 56 children at the time of     
     flexible bronchoscopy and bronchoalveolar lavage. 
Characteristics    
 
Median (range) age (years) 
  
2.2 (0.8-9.8)   
Males   
 
32 (57%) 
Indigenous Australian   52 (93%) 
 
Chronic cough   
 
41 (75%) 
Current nasal discharge 
 
33 (60%) 
History of wheezing 
 
          Previous 
 
          Current (within the last 12-months) 
 
29 (53%) 
 
26 (47%) 
 
17 (31%) 
Respiratory hospitalizations >2 
  
30 (55%) 
 
Current antibiotic use* 
 
26 (46%) 
Current inhaled corticosteroids 
 
5 (9%) 
≥ 2 doses conjugate pneumococcal vaccine  53 (95%) 
  
CT scan evidence of bronchiectasis †  
 
           No. of lobes involved:    1 
                                                   2 
                                                   3 
                                                   4 
 5 
52 (93%) 
 
10 (19%) 
25 (48%) 
9 (17%) 
6 (12%) 
2 (4%) 
 
CT, computed tomographic; * azithromycin 20, roxithromycin 1, trimethoprim-sulfamethoxazole 1, 
amoxicillin 4; † 51/52 were Indigenous Australian children, remaining 4 had chronic suppurative 
lung disease.    
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Figure 1. Distribution of eosinophils (a) and neutrophils (b) as a percentage of total airway leukocytes in 
bronchoalveolar lavage fluid from 55 children with bronchiectasis or chronic suppurative lung disease. The 
lower limit for clinically important airway eosinophilia (2.5%) is represented by the dashed line. The y axis is 
a split scale. Cytoslides of BAL show eosinophilia with neutrophilia (c) original x400 and neutrophilia (d) 
original x200.  
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Figure 2.  
Scatter plot of eosinophil percentages in bronchoalveolar lavage fluid and absolute eosinophil counts in 
peripheral blood (n=54), r=0.49, P=0.0002. Open circles identify children with positive strongyloides 
serology (enzyme immunoassay >0.45 absorbance units). Thresholds for circulating and airway eosinophilia 
are shown by the dashed lines  
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Table 2: Current wheeze and peripheral blood eosinophilia as predictors of airway 
eosinophilia 
 PPV % 
(95% CI) 
NPV % 
(95% CI) 
Sensitivity  
% (95% CI) 
Specificity 
% (95% CI) 
Current Wheeze 
(in last 12-mths) 
28 
(11, 54) 
59 
(39, 76) 
29 
(11, 56) 
56 
(38, 74) 
 
Blood 
eosinophilia 
(1.5x10
9
/L) 
 
73 
(39, 93) 
 
74 
(59, 86) 
 
42 
(21, 66) 
 
91 
(75, 98) 
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PPUL-11-0337_ResponseToReviewers_Appendix2, showing a slice of HRCT scan which was reported by local 
radiologist as “no bronchiectasis”. However, this CT was interpreted as having bronchiectasis in LLL and 
borderline bronchiectatic changes in RLL by the paediatric pulmonologist, taking into account the child’s 
clinical history as well. This highlights the disparity of opinions on CT reporting by adult-based radiologist 
compared to paediatric specialists.  
This image is a supplement to the the response to Reviewer 2, comment 2 only and is not for publication.  
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